The activities of the metalloproteinase gelatinase B, and the presence of IL-6, an inducer of metalloproteinase inhibitors, were investigated in CSF samples of 190 patients with multiple sclerosis (MS; n = 55), optic neuritis (ON; n = 46), other inflammatory neurological diseases (OIND; n = 27) or control patients (CON) with non-inflammatory neurological diseases (n = 62). IL-6, measurable as hybridoma growth factor activity (detection limit 3 pg/ml), was found in only four of these 190 CSF samples (three OIND, one CON). Elevated CSF gelatinase B levels were detected in 40%, 35% and 54% of the patients with MS, ON and OIND, respectively, while all control CSFs were devoid of gelatinase B activity. Clinical and laboratory data were compared with gelatinase B levels. No correlation was found between the CSF cytoses and gelatinase B levels, suggesting that this enzyme in the CSF originates from CNS lesions rather than from CSF cells. However, the occurrence of the gelatinase B significantly correlated with the IgG index in the MS patient group. This study stimulates further investigation into the possible usage of protease inhibition in demyelinating diseases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1468-1331.1994.tb00051.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!